Filing summary
Important entity and period note: The supplied filing is ARYA Sciences Acquisition Corp. III’s Form 10-K, not an operating-company 10-K for Nautilus Biotechnology, Inc. It covers ARYA’s fiscal year ended December 31, 2020 (incorporated March 27, 2020) and reports no Nautilus operating results. Nautilus appears as the proposed merger target in a subsequent-event disclosure.
Business context and reporting period
ARYA was a blank-check company formed to pursue a business combination, with a stated focus on healthcare, life sciences, and medical technology. Its 2020 activity was formation, its August 2020 IPO, and searching for a target; it had no operating revenue or business operations.
Key financial metrics
| Metric | Period or date | Amount |
|---|---|---|
| Revenue | Inception through December 31, 2020 | None |
| General and administrative expenses | Inception through December 31, 2020 | $576,035 |
| Trust-account investment gains, dividends, and interest | Inception through December 31, 2020 | $52,952 |
| Net loss | Inception through December 31, 2020 | $523,083 |
| Cash and cash equivalents outside trust | December 31, 2020 | $1,001,032 |
| Investments held in trust | December 31, 2020 | $149,552,952 |
| Current assets / current liabilities | December 31, 2020 | $1,304,791 / $388,507 |
| Working capital | December 31, 2020 | Approximately $916,000 |
| Deferred underwriting commissions | December 31, 2020 | $5,232,500 |
| Cash flow from operations | Inception through December 31, 2020 | $(549,570) |
There was no debt outstanding at year-end; the filing reports no long-term debt obligations. The 2020 IPO raised $149.5 million gross, and the sponsor’s private placement raised approximately $5.0 million. About $14.0 million of Class A shares were classified as temporary equity because they were redeemable. Margins are not meaningful for a pre-combination shell. The filing provides no prior comparable operating period.
Material changes and subsequent transaction
ARYA entered into a business combination agreement with Nautilus on February 7, 2021, after the 2020 year-end. The proposed transaction valued Nautilus at an implied $900 million equity value and included a committed PIPE subscription for 20 million shares at $10 per share, or $200 million gross. The filing expected closing in the second quarter of 2021, subject to shareholder approval and other customary conditions; it was not completed as of December 31, 2020.
Outlook, risks, and unusual items
- Management expected available working capital and potential sponsor or affiliate borrowing capacity to fund activity through a business combination or one year from the filing, but such loans were not committed.
- ARYA had 24 months from its IPO closing to complete a business combination, or it would wind up and redeem public shares, subject to creditor claims and other terms. The filing’s text is inconsistent about the exact deadline: it generally states August 11, 2022, while one note refers to October 26, 2022.
- Key risks include failure to complete the transaction before the deadline, shareholder redemptions reducing cash available at closing, the need for additional financing, COVID-19-related disruption, competition for targets, and conflicts of interest arising from management’s other Perceptive Advisors and SPAC affiliations.
- The sponsor agreed to a $10 million-per-month administrative-support arrangement; approximately $48,000 was incurred in 2020. The sponsor also indicated interest in purchasing up to $25 million of shares at the proposed combination, but this indication was nonbinding.
- Management stated that COVID-19’s specific financial impact was not readily determinable; the financial statements include no adjustment for that uncertainty. No material litigation was reported.
Most important facts for investors to verify
- Confirm the filing and issuer: these audited results are for ARYA, not Nautilus Biotechnology; obtain Nautilus’s own financial statements for its operating performance.
- Verify the final transaction status, closing date, shareholder approval, redemption level, and cash delivered at closing.
- Review the definitive transaction terms, including the $900 million implied Nautilus equity value, $200 million PIPE, share issuance, dilution, lock-ups, and any related-party participation.
- Reconcile the business-combination deadline discrepancy in the filing and confirm the governing charter date.
- Assess the trust balance, deferred underwriting fee, sponsor indemnity capacity, and creditor-claim exposure when evaluating redemption value.